EP3784265A4 - Zyklische thioether-peptid-amylin-rezeptormodulatoren - Google Patents

Zyklische thioether-peptid-amylin-rezeptormodulatoren Download PDF

Info

Publication number
EP3784265A4
EP3784265A4 EP19791705.7A EP19791705A EP3784265A4 EP 3784265 A4 EP3784265 A4 EP 3784265A4 EP 19791705 A EP19791705 A EP 19791705A EP 3784265 A4 EP3784265 A4 EP 3784265A4
Authority
EP
European Patent Office
Prior art keywords
amylin
receptor modulators
thioether peptide
cyclic
cyclic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19791705.7A
Other languages
English (en)
French (fr)
Other versions
EP3784265A2 (de
Inventor
Wenying Jian
Raymond Patch
Rui Zhang
Songmao ZHENG
Simon Hinke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP3784265A2 publication Critical patent/EP3784265A2/de
Publication of EP3784265A4 publication Critical patent/EP3784265A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19791705.7A 2018-04-25 2019-04-17 Zyklische thioether-peptid-amylin-rezeptormodulatoren Withdrawn EP3784265A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662492P 2018-04-25 2018-04-25
PCT/IB2019/053194 WO2019207427A2 (en) 2018-04-25 2019-04-17 Thioether cyclic peptide amylin receptor modulators

Publications (2)

Publication Number Publication Date
EP3784265A2 EP3784265A2 (de) 2021-03-03
EP3784265A4 true EP3784265A4 (de) 2022-06-22

Family

ID=68293854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19791705.7A Withdrawn EP3784265A4 (de) 2018-04-25 2019-04-17 Zyklische thioether-peptid-amylin-rezeptormodulatoren

Country Status (5)

Country Link
EP (1) EP3784265A4 (de)
JP (1) JP2021522231A (de)
CN (1) CN112074289A (de)
CA (1) CA3097812A1 (de)
WO (1) WO2019207427A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN114057862A (zh) * 2021-12-14 2022-02-18 安徽省国平药业有限公司 一种glp-1(1-37)多肽的合成方法
CN120040558A (zh) * 2024-03-19 2025-05-27 深圳湾实验室 多肽或其类似物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050059A1 (en) * 1997-05-06 1998-11-12 Amylin Pharmaceuticals, Inc. Method for preventing gastritis using amylin or amylin agonists
WO2005115437A2 (en) * 2004-05-20 2005-12-08 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
EP2036923A1 (de) * 2007-09-11 2009-03-18 Novo Nordisk A/S Verbesserte Derivate von Amylin
WO2010144508A1 (en) * 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011050008A2 (en) * 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
WO2011084808A2 (en) * 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
KR20140045433A (ko) * 2011-05-25 2014-04-16 아밀린 파마슈티칼스, 엘엘씨. 아밀린 펩티드 및 그의 유도체 및 용도
US20140249076A1 (en) * 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
CN105612174A (zh) * 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的二硫化物环状多肽
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EP3368556B1 (de) * 2015-10-28 2024-04-10 Tufts University Neuartige polypeptide mit verbesserter proteolytischer stabilität und verfahren zur herstellung und verwendung davon

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050059A1 (en) * 1997-05-06 1998-11-12 Amylin Pharmaceuticals, Inc. Method for preventing gastritis using amylin or amylin agonists
WO2005115437A2 (en) * 2004-05-20 2005-12-08 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLL G N ET AL: "A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges", DRUG DISCOVERY TODAY: TECHNOLOGIES, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 1-4, January 2009 (2009-01-01), pages e13 - e18, XP027503974, ISSN: 1740-6749, [retrieved on 20090419], DOI: 10.1016/J.DDTEC.2009.03.001 *

Also Published As

Publication number Publication date
CN112074289A (zh) 2020-12-11
WO2019207427A2 (en) 2019-10-31
JP2021522231A (ja) 2021-08-30
EP3784265A2 (de) 2021-03-03
WO2019207427A3 (en) 2020-01-02
CA3097812A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
DK3743406T3 (da) Tmem16a modulatorer
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
EP3619310A4 (de) Modulatorische polynukleotide
EP3570785A4 (de) Justierung von sehnenfäden
SI3507276T1 (sl) Spojine modulatorja toličnih receptorjev
DK3875414T3 (da) Fastgørelsesindretning
EP3899024A4 (de) Modulatoren der hsd17b13-expression
DK3729990T3 (da) Fastgørelsesanordning
EP3442971C0 (de) Östrogenrezeptormodulatoren
DK3646748T3 (da) Fastgørelsesanordning
HUE062866T2 (hu) TREX-1 modulátorok
IL281492A (en) Modulators of pnpla3 expression
EP3580223A4 (de) Benzothiophen-östrogenrezeptormodulatoren
DK3359160T3 (da) Farnesoid x receptor modulatorer
EP3565543A4 (de) Mu-opioid-rezeptormodulatoren
EP4101404C0 (de) Einführvorrichtungen
EP3724220A4 (de) Nkg2d-daric-rezeptoren
PT3568609T (pt) Dispositivo de fixação
HUE047761T2 (hu) Ösztrogén receptor modulátorok
EP3694528A4 (de) Mtorc1-modulatoren
IL285074A (en) Gpr35 modulators
EP3784265A4 (de) Zyklische thioether-peptid-amylin-rezeptormodulatoren
EP3793748C0 (de) Applikator
EP3641588C0 (de) Applikatorvorrichtung
EP3779540A4 (de) Optischer modulator

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220520

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/72 20060101ALI20220516BHEP

Ipc: C07K 14/47 20060101ALI20220516BHEP

Ipc: A61P 3/10 20060101ALI20220516BHEP

Ipc: A61P 1/16 20060101ALI20220516BHEP

Ipc: A61K 38/17 20060101AFI20220516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221220